Matt Gorovoy, Phd, Mba Email & Phone Number

California, United States

Washington, District Of Columbia, US

Washington, District Of Columbia, US

Waltham, MA, US

Rapid diagnostic testing, transplant diagnostics.

Waltham, MA, US

• COVID Dx solutions productization strategy development and execution across the company
• Leader of 12 workstreams across the company
• Daily management and coordination of organic and inorganic efforts aimed to develop and commercialize COVID Dx solutions

Waltham, MA, US

• BioPharma services, Diagnostics.
• P&L owner and commercial leader for >$100M business.
• Leading direct and matrixed organization of 70+ (commercial, marketing, PMO, QA/QC, R&D, operations and manufacturing)
• Site leader for strategy, BD and M&A activities

Waltham, MA, US

• Diagnostics, BioPharma Services global Head of BD/Sales (direct and regional matrix).
• >$100M revenue generating responsibilities.
• Head of Companion Diagnostics (cradle-to-grave ownership of CDx programs)
• Site leader for strategy, BD and M&A activities

Waltham, MA, US

• Graduate of Thermo Fisher Scientific GM Development program

Waltham, MA, US

• P&L ownership and management for >$1B business unit (qPCR and CE businesses)
• Led deal valuation for business development and M&A activities, 5Y strategic plan development

Waltham, MA, US

• Led 5Y strategic plan development for >$2B division
• Drove organic and inorganic portfolio prioritization across five businesses
• Led deal valuation for business development and M&A activities

Waltham, MA, US

• Led development and launch of Ion Chef NGS instrument
• Full product line ownership (upstream and downstream marketing)
• Led development and execution of global commercialization strategy
• Enabled commercial readiness (sales, service, support infrastructure); KOL/accounts management
• Drove global placement of instruments; exceeded revenue goal by >200%

San Diego, CA, US

• Market Sectors: BioPharma Services, Companion/molecular diagnostics, Oncology / InflammationResponsibilities:
• Business development: developed, negotiated and executed various types of agreements including partnerships, collaborations and IP licensing cases. Led negotiations from initial contact through development of terms and.
• Corporate development: reporting directly to the CEO - development and execution of corporate strategy
• Drove implementation and customization of Salesforce CRM

• Augmented Reality, Inc.; NanoVision Biotech, Inc.; The Boxing Club; Trice Imaging, Inc.; Interactive Biosoftware; KAER Biotherapeutics; Targeson, Inc.; OncoFluor, Inc.; GenWay Biotech, Inc.; and others.Market sectors:
• Therapeutics
• Medical devices
• Software/data analytics
• DiagnosticsProjects scope:o Business plan creationo Investor pitch/Fundraisingo Technology/IP assessment o Marketing strategy o Commercialization strategy

La Jolla, CA, US

• Department of Pathology.
• Discovered a novel biomarker of inflammation and developed a diagnostic assay (rheumatoid arthritis, systemic lupus erythematosus).
• Secured independent funding from NIH/Immunology.

Chicago, IL, US

• Department of Pharmacology.
• Integrated and led two research teams that discovered 2 drug targets (vascular leakage; and ocular inflammation and fibrosis) (published 4 papers and filed a patent application).

Chicago, IL, US

• Formulated a hypothesis; then led a research team that investigated the role of LIM kinase 1 in inflammation-induced endothelial cell contractility (published in Journal of Biological Chemistry).
• Secured independent funding from American Heart Association (2004-2006) to study the role of LIM kinase 1 in endothelial cell contractility during inflammation.

Development of high-throughput method of DNA sequencing; chemical modification of nucleotides (DNA), development of diagnostic tests (PCR and DNA hybridization), development of "molecular beacon" system, oligonucleotide synthesis,

Mba, Strategy/Finance

Nih Postdoctoral Fellow, Pathology

Phd, Molecular And Cellular Pharmacology

M.S. With Honors, Organic Chemistry